Use of infliximab in particular clinical settings: management based on current evidence.

Alfredo Papa, Giammarco Mocci, Michele Bonizzi, Carla Felice, Gianluca Andrisani, Italo De Vitis, Luisa Guidi, Antonio Gasbarrini

Risultato della ricerca: Contributo in rivistaArticolo in rivista

40 Citazioni (Scopus)


With the increasingly widespread use of the anti-tumor necrosis factor-alpha agent infliximab for the treatment of Crohn's disease and ulcerative colitis, there have been some concerns raised about the potential consequences of such therapy in particular clinical settings. In this review, we report the current strategies for optimizing treatment outcomes and minimizing the risks of some of the most serious events attributable to infliximab therapy. In particular, an up-to-date overview is provided on how to treat patients with inflammatory bowel disease using infliximab therapy, with regard to the diagnosis and management of latent tuberculosis infection and the risk of reactivation of hepatitis B and C infections. Furthermore, based on the available evidence, we evaluate the possibility of using infliximab during pregnancy. Finally, we evaluate whether patients with malignancies or pre-neoplastic lesions could be candidates for infliximab therapy. Overall, this review will provide physicians who use infliximab for the treatment of inflammatory bowel disease with several practical recommendations for the management of some complex situations that may occur in daily clinical practice.
Lingua originaleEnglish
pagine (da-a)1575-1586
Numero di pagine12
Stato di pubblicazionePubblicato - 2009


  • infliximab


Entra nei temi di ricerca di 'Use of infliximab in particular clinical settings: management based on current evidence.'. Insieme formano una fingerprint unica.

Cita questo